On the seventh day after receiving the first special call, the FDA announced an emergency approval notice, allowing K Therapy to proceed with Phase II clinical trials in the United States, with conditions of strict safety monitoring and data collection. The important thing is that the door has opened.
Almost simultaneously, twelve major regulatory agencies, including the EMA, the UK Medicines Agency, the Japan Medicines Agency, and the Australia Medicines Agency, issued similar authorizations.
These decisions were driven not by pharmaceutical company lobbying reports or government policy studies, but by the real voices of patients' families on social networks, the public appeals of experts and scholars in mainstream media, and the large number of letters from voters to congressional offices and their active lobbying efforts.
Huang Jiacai looked at these announcements with complex emotions.
